The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world’s biggest diagnostics companies being thrust into the limelight Siemens Healthineers, GE Healthcare, Roche, and Abbott are the top players in the race of the global diagnostic companies. The companies are […]Read More
BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Published: May 21, 2021 | Tags: BeiGene, Tislelizumab, CT, P-III, RATIONALE 309 Study, Recurrent, Metastatic Nasopharyngeal Cancer Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR […]Read More
The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of […]Read More
Shots: Abbott has received CE Mark for Navitor making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk Navitor uses Abbott’s FlexNav delivery system along with a unique design for preventing blood leaking around the valve to provide a less invasive alternative to […]Read More
In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson’s and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in the US that allows patients to receive treatment from the doctor without leaving home. Shots: Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with […]Read More
BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority Review, nivolumab, Muscle Invasive Urothelial Carcinoma Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma Published: Apr 30, 2021 | […]Read More
Shots: Abbott’s new imaging platform powered by Ultreon 1.0 software has received a CE mark in the EU. The new imaging platform merges optical coherence tomography (OCT) with AI to enhance visualization and detect the severity of calcium-based blockages and measure vessel diameter Ultreon software when integrated with Abbott’s new Dragonfly OpStar imaging catheter allows […]Read More
In an interview with PharmaShots, Allen Burton, M.D., Medical Director at Abbott Neuromodulation shared his views on the NeuroSphere myPath App which is designed to track and report pain relief in chronic pain patients. Shot: The app will record pain relief during the device trial period with SCS or DRG therapy, simplifying reporting outcomes & […]Read More
PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support, Development, Commercialization, Bentracimab Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan Published: Mar 12, 2021 | Tags: […]Read More
Shots: The coalition builds on Abbott’s excellence in virus surveillance and aid in analyzing virus samples for unknown diseases and detects mutations and variants including COVID-19 The goal of the Pandemic Defense Coalition is to identify new pathogens, analyze potential risk level, assess public health impact in real-time, and contain outbreaks when new virus threats […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
